A Study of LY2951742 for Patients with Episodic Cluster Headaches

Overview

About this study

The main purpose of this study is to evaluate the effectiveness and safety of the study drug known as LY2951742 for the treatment of patients who have episodic cluster headaches.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • A history of episodic cluster headache with at least two cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of ≥1 month
  • Able to distinguish cluster headache attacks from other headaches

Exclusion Criteria

  • Current enrollment in or discontinuation within the last 30 days from a clinical trial involving any investigational drug or device
  • Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF)
  • Is taking indomethacin and/or suspected of having another distinct trigeminal autonomic cephalalgia
  • A history of migraine variants that could implicate or could be confused with ischemia
  • Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins
  • A history or presence of other medical illness that indicates a medical problem that would preclude study participation
  • Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator
  • Pregnant or nursing

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Todd Rozen, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions